Do Antipsychotics Limit Disability in Schizophrenia? A Naturalistic Comparative Study in the Community

Overview

Journal Indian J Psychiatry

Specialty Psychiatry

Date 2010 Feb 23

PMID 20174516

Citations 13

Authors

Jagadisha Thirthalli

Basappa K Venkatesh

Magadi N Naveen

Ganesan Venkatasubramanian

Udupi Arunachala

Kengeri V Kishore Kumar

Bangalore N Gangadhar

Affiliations

Soon will be listed here.

Abstract

Background: Though antipsychotics are effective against symptoms of schizophrenia and prevent relapses, their effect on disability has not been studied in a comparative design.

Aim: To compare disability of schizophrenia patients receiving continuous antipsychotic treatment with that of those not receiving or receiving irregular treatment in a rural community setting using a naturalistic comparative study design.

Patients And Methods: Disability was assessed in 182 schizophrenia patients living in Thirthahalli Taluk of Shimoga District, Karnataka, using Indian Disability Evaluation and Assessment Scale (IDEAS). Fifty patients (27.5%) were receiving regular treatment in the previous 2 years and their disability was assessed for the period when they were on antipsychotics. The remaining 132 patients (72.5%) had off-antipsychotics periods in the previous 2 years and their disability was assessed for the period when they were off-antipsychotics.

Results: Patients on antipsychotics had significantly less disability across all domains of disability and in total IDEAS scores. Multivariate regression analysis showed that treatment status predicted disability scores after controlling for the effects of the confounding factors. Different levels of exposure to antipsychotic treatment were associated with different levels of disability.

Conclusions: Treatment with antipsychotics is associated with significantly less disability. There is an urgent need to bring schizophrenia patients under the umbrella of treatment.

Citing Articles

Mental Health Programme in India: Has the tide really turned?.

Gangadhar B, Kumar C, Sadh K, Manjunatha N, Math S, Kalaivanan R Indian J Med Res. 2023; 157(5):387-394.

PMID: 37955215 PMC: 10443714. DOI: 10.4103/ijmr.IJMR_2217_20.

Medical Council of India regulations for entry into graduate medical courses: Unfair barriers for persons with disability due to mental illness.

Angothu H, Jadhav P, Jayarajan D, Thanapal S, Muliyala K Indian J Psychiatry. 2021; 63(5):506-507.

PMID: 34789941 PMC: 8522603. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_1226_20.

The magnitude of disability in patients with schizophrenia in North West Ethiopia: A multicenter hospital-based cross-sectional study.

Beyene G, Legas G, Azale T, Abera M, Asnakew S Heliyon. 2021; 7(5):e07053.

PMID: 34041398 PMC: 8141773. DOI: 10.1016/j.heliyon.2021.e07053.

Disability in clinically stable patients of schizophrenia.

Sharma M, Nischal A, Nischal A, Agarwal M, Gupta B, Kar S Ind Psychiatry J. 2021; 29(1):61-67.

PMID: 33776277 PMC: 7989458. DOI: 10.4103/ipj.ipj_82_20.

Change in attitude of ASHAs towards persons with mental illnesses following participation in community based rehabilitation project.

James J, Sivakumar T, Kumar C, Thirthalli J Asian J Psychiatr. 2019; 46:51-53.

PMID: 31610519 PMC: 10290773. DOI: 10.1016/j.ajp.2019.09.031.

References

McGurk S, Moriarty P, Harvey P, Parrella M, White L, Davis K . The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia. Schizophr Res. 2000; 42(1):47-55. DOI: 10.1016/s0920-9964(99)00097-3. View

Loebel A, Lieberman J, Alvir J, Mayerhoff D, Geisler S, Szymanski S . Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992; 149(9):1183-8. DOI: 10.1176/ajp.149.9.1183. View

Bowie C, Reichenberg A, Patterson T, Heaton R, Harvey P . Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry. 2006; 163(3):418-25. DOI: 10.1176/appi.ajp.163.3.418. View

Hegarty J, Baldessarini R, Tohen M, Waternaux C, Oepen G . One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994; 151(10):1409-16. DOI: 10.1176/ajp.151.10.1409. View

DeQuardo J, Tandon R . Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?. J Psychiatr Res. 1998; 32(3-4):229-42. DOI: 10.1016/s0022-3956(98)00024-7. View

Edwards J, Maude D, McGorry P, Harrigan S, Cocks J . Prolonged recovery in first-episode psychosis. Br J Psychiatry Suppl. 1998; 172(33):107-16. View

Tandon R . In conclusion: does antipsychotic treatment modify the long-term course of schizophrenic illness?. J Psychiatr Res. 1998; 32(3-4):251-3. View

Johnson D, Pasterski G, Ludlow J, Street K, Taylor R . The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand. 1983; 67(5):339-52. DOI: 10.1111/j.1600-0447.1983.tb00351.x. View

Craig T, Bromet E, Fennig S, Lavelle J, Galambos N . Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?. Am J Psychiatry. 2000; 157(1):60-6. DOI: 10.1176/ajp.157.1.60. View

10.

Ho B, Andreasen N, Flaum M, Nopoulos P, Miller D . Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am J Psychiatry. 2000; 157(5):808-15. DOI: 10.1176/appi.ajp.157.5.808. View

11.

Kurtz M . Symptoms versus neurocognitive skills as correlates of everyday functioning in severe mental illness. Expert Rev Neurother. 2006; 6(1):47-56. DOI: 10.1586/14737175.6.1.47. View

12.

Wyatt R, Green M, TUMA A . Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychol Med. 1997; 27(2):261-8. DOI: 10.1017/s0033291796004345. View

13.

Wyatt R . Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991; 17(2):325-51. DOI: 10.1093/schbul/17.2.325. View

14.

Curson D, Barnes T, Bamber R, Platt S, Hirsch S, Duffy J . Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic. Br J Psychiatry. 1985; 146:464-9. DOI: 10.1192/bjp.146.5.464. View

15.

Whitaker R . The case against antipsychotic drugs: a 50-year record of doing more harm than good. Med Hypotheses. 2004; 62(1):5-13. DOI: 10.1016/s0306-9877(03)00293-7. View

16.

Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine J . Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004; 291(21):2581-90. DOI: 10.1001/jama.291.21.2581. View

17.

Velligan D, Mahurin R, Diamond P, Hazleton B, Eckert S, Miller A . The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res. 1997; 25(1):21-31. DOI: 10.1016/S0920-9964(97)00010-8. View

18.

Mohan I, Tandon R, Kalra H, Trivedi J . Disability assessment in mental illnesses using Indian Disability Evaluation Assessment Scale (IDEAS). Indian J Med Res. 2005; 121(6):759-63. View

19.

Turner T . Long term outcome of treating schizophrenia. BMJ. 2004; 329(7474):1058-9. PMC: 526107. DOI: 10.1136/bmj.329.7474.1058. View